Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL141413 | 0.91 | FFAR1 (0.52) | FFAR1USP30SCDDGAT1ROCK2 | |
| SCHEMBL19341509 | 0.86 | FFAR1 (0.44) | FFAR1USP30SCDDGAT1ROCK2 | |
| SCHEMBL18202880 | 0.84 | FFAR1 (0.43) | FFAR1USP30SCDDGAT1ROCK2 | |
| SCHEMBL20733996 | 0.84 | FFAR1 (0.45) | FFAR1USP30SCDDGAT1ROCK2 | |
| SCHEMBL19672040 | 0.83 | FFAR1 (0.44) | FFAR1USP30SCDDGAT1ROCK2 | |
| SCHEMBL19964091 | 0.82 | FFAR1 (0.40) | FFAR1USP30SCDROCK2NR1H2 | |
| SCHEMBL23360896 | 0.81 | FFAR1 (0.40) | FFAR1USP30SCDDGAT1ROCK2 | |
| SCHEMBL22334710 | 0.80 | FFAR1 (0.42) | FFAR1USP30SCDDGAT1ROCK2 | |
| SCHEMBL12510896 | 0.80 | FFAR1 (0.36) | FFAR1USP30SCDROCK2NR1H2 | |
| SCHEMBL23349424 | 0.79 | SCD (0.38) | FFAR1USP30SCDROCK2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | FFAR1 2045/4885USP30 3003/4885SCD 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.